Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Study of immunohistochemistry in prostatic lesions with special reference to proliferation and invasiveness.

Manna AK, Pathak S, Gayen P, Sarkar DK, Kundu AK.

Indian J Surg. 2011 Apr;73(2):101-6. doi: 10.1007/s12262-010-0180-7. Epub 2010 Nov 18.

2.

Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.

Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA.

Am J Surg Pathol. 2002 Sep;26(9):1161-8.

PMID:
12218572
3.

Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions.

Garg M, Kaur G, Malhotra V, Garg R.

Prostate Int. 2013;1(4):146-51. doi: 10.12954/PI.13026. Epub 2013 Dec 30.

4.

Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations.

Shah RB, Kunju LP, Shen R, LeBlanc M, Zhou M, Rubin MA.

Am J Clin Pathol. 2004 Oct;122(4):517-23.

PMID:
15487448
5.

Immunohistochemistry in diagnostic surgical pathology of the prostate.

Hameed O, Humphrey PA.

Semin Diagn Pathol. 2005 Feb;22(1):88-104. Review.

PMID:
16512601
6.

Role of cyclin D1 immunoreactivity and AgNOR staining in the evaluation of benign and malignant lesions of the prostate.

Gupta V, Garg M, Chaudhry M, Singh S, Sen R, Gill M, Sangwaiya A.

Prostate Int. 2014;2(2):90-6. doi: 10.12954/PI.14041. Epub 2014 Jun 30.

7.

Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.

Zhou M, Shah R, Shen R, Rubin MA.

Am J Surg Pathol. 2003 Mar;27(3):365-71.

PMID:
12604893
9.
10.

Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate.

Molinié V, Fromont G, Sibony M, Vieillefond A, Vassiliu V, Cochand-Priollet B, Hervé JM, Lebret T, Baglin AC.

Mod Pathol. 2004 Oct;17(10):1180-90.

11.

Role of proliferative markers in prostatic lesions.

Ghosh J, Burman A, Manna AK, Chatterjee A.

Indian J Pathol Microbiol. 2004 Jul;47(3):354-8.

PMID:
16295423
12.
13.

Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.

Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA.

Hum Pathol. 2004 Dec;35(12):1462-8.

PMID:
15619204
14.
15.

[The application of high molecular weight cytokeratin in differential diagnosis of prostate adenocarcinoma].

Kong X, Deng F, Wang J.

Zhonghua Bing Li Xue Za Zhi. 1996 Aug;25(4):199-201. Chinese.

PMID:
9275650
16.

p63 is more sensitive and specific than 34βE12 to differentiate adenocarcinoma of prostate from cancer mimickers.

Kalantari MR, Anvari K, Jabbari H, Tabrizi FV.

Iran J Basic Med Sci. 2014 Jul;17(7):497-501.

18.

Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate.

Yang XJ, Wu CL, Woda BA, Dresser K, Tretiakova M, Fanger GR, Jiang Z.

Am J Surg Pathol. 2002 Jul;26(7):921-5.

PMID:
12131160
19.

Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.

Boran C, Kandirali E, Yilmaz F, Serin E, Akyol M.

Urol Oncol. 2011 Nov-Dec;29(6):614-23. doi: 10.1016/j.urolonc.2009.11.013. Epub 2010 Mar 2.

PMID:
20189848
20.

Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.

Goel T, Garg S.

Urol Int. 2009;82(3):286-90. doi: 10.1159/000209359. Epub 2007 Apr 16.

PMID:
19440015

Supplemental Content

Support Center